Please login to the form below

Not currently logged in
Email:
Password:

Generex publishes Oral-Lyn study

Generex has published the results of a Oral-lyn study in the Diabetes Technology & Therapeutics journal covering new technology and products for the treatment, monitoring, diagnosis and prevention of diabetes

Generex Biotechnology, a US developer of buccal drug delivery for metabolic diseases, has published the results of a Oral-lyn study in Diabetes Technology & Therapeutics, a peer-reviewed journal covering new technology and products for the treatment, monitoring, diagnosis and prevention of diabetes.

Oral-lyn buccal spray uses Generex's proprietary drug delivery technology, RapidMist, which administers medications directly into the mouth as a metered-dose spray, for rapid absorption by the buccal mucosa.

The study, entitled 'Comparison of Oral Insulin Spray and Subcutaneous Regular Insulin at Mealtime in Type 1 Diabetes' was led by Dr Jaime Guevara-Aguirre, Dr Marco Guevara-Aguirre, Dr Jeannette Saavedra, Dr Gerald Bernstein and Dr Arlan L Rosenbloom.

The results of the study showed that regular insulin and Oral-lyn had similar glucodynamic effects in subjects with type 1 diabetes receiving a twice-daily insulin analogue as baseline therapy.

Monitoring and baseline corrections with additional snacks, subcutaneous regular insulin or Generex Oral-lyn puffs resulted in glycaemic control as assessed by individual daily glycaemic responses, while normal pre-prandial glycation decreased, but not significantly.

Dr Gerald Bernstein, Generex's vice-president of medical affairs and a co-author of the article, said: "This publication is significant in that it shows consistently and clearly that equivalent amounts of Generex Oral-lyn and injected regular insulin will yield comparable blood glucose control."

Generex launched Oral-Lyn in South America in 2005.

16th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Red Health

Red Health was formed in 2007 to bring something fresh to the healthcare PR world. Our approach was simple –...

Latest intelligence

What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...
PANDAS/PANS Awareness: A parent’s story
To help raise awareness of these often underdiagnosed diseases, Jon Hallows, Joint MD at Porterhouse shares his own experience as a parent of a son recently diagnosed with PANDAS...
Iskra Reic
Leading AstraZeneca’s return to growth in Europe
PME talks to Iskra Reic, the company’s head of Europe and Canada...

Infographics